Michael Barbella, Managing Editor12.16.23
A new partnership, purchase, personnel move, and patent dispute were MPO website favorites this past week.
ResMed topped pageviews with word of its legal victory against New York University (NYU). A U.S. Patent Trial and Appeals Board ruling invalidated alleged patent infringement claims NYU filed against the company in June 2021, based on seven NYU patents. NYU's complaint claimed the AutoSet and AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators infringed one or more claims of seven NYU patents. ResMed, however, conteded the claims were invalid.
Runner-up to ResMed's news was Integra LifeSciences' announcement about acquiring Acclarent from Ethicon—a Johnson & Johnson MedTech company—for $275 million in closing with further $5 million upon achievement of regulatory milestones. Acclarent specializes in ear, nose, and throat technologies and the acquisition positions Integra to be a key player in the ENT segment.
Medtronic drove significant site traffic by expanding its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals, while AdvaMed followed suit by naming a new chairman.
NeuroOne also enticed cybervisitors to the site by gaining FDA 510(k) clearance to market its OneRF Ablation System for creating radiofrequency lesions in nervous tissue for functional neurosurgical procedures.
ResMed topped pageviews with word of its legal victory against New York University (NYU). A U.S. Patent Trial and Appeals Board ruling invalidated alleged patent infringement claims NYU filed against the company in June 2021, based on seven NYU patents. NYU's complaint claimed the AutoSet and AutoRamp features of ResMed’s AirSense 10 AutoSet flow generators infringed one or more claims of seven NYU patents. ResMed, however, conteded the claims were invalid.
Runner-up to ResMed's news was Integra LifeSciences' announcement about acquiring Acclarent from Ethicon—a Johnson & Johnson MedTech company—for $275 million in closing with further $5 million upon achievement of regulatory milestones. Acclarent specializes in ear, nose, and throat technologies and the acquisition positions Integra to be a key player in the ENT segment.
Medtronic drove significant site traffic by expanding its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals, while AdvaMed followed suit by naming a new chairman.
NeuroOne also enticed cybervisitors to the site by gaining FDA 510(k) clearance to market its OneRF Ablation System for creating radiofrequency lesions in nervous tissue for functional neurosurgical procedures.